Genelux
GNLXGenelux Corporation is a late clinical-stage public company (Nasdaq: GNLX) developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogen …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2024-2026
All insider trades at Genelux
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 6/3/2026 | Sell | Smalling, Ralph | Head of Regulatory | $2.9 | $563 |
| 6/1/2026 | Sell | Thomas, John | Director | $3.0 | $29,801 |
| 5/11/2026 | Sell | Smalling, Ralph | Head of Regulatory | $3.0 | $804 |
| 5/11/2026 | Sell | Zindrick, Thomas | President and CEO | $2.9 | $8,226 |
| 5/11/2026 | Sell | Yu, Yong | Chief Scientific Officer | $3.0 | $1,798 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)